Clinical trial · Observational
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing on Chemotherapy, Treated With 177 Lu-PSMA (PROFLu)D7 (± 1 Day)
NCT06460454CI-TRIAL-00086755PROFLucompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET scan of 18F-FDG | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients treated with 177Lu-PSMA for castration-resistant prostate cancer
- description
- Patients treated with 177Lu-PSMA for castration-resistant prostate cancer and who benefited from 68Ga-PSMA and 18FDG PET scans as part of the initial workup and treatment follow-up.
- interventionNames
- Device: PET scan of 18F-FDG
Primary outcomes (1)
- measure
- Diagnostic accuracy of 18FDG PET metabolic volume
- timeFrame
- 1 year
- description
- Diagnostic accuracy of 18FDG PET metabolic volume in predicting 1-year overall survival.
Secondary outcomes (3)
- measure
- Diagnostic accuracy of 18FDG PET tumor parameter (SUVmax)
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients treated with 177Lu-PSMA for castration-resistant prostate cancer at Nancy University Hospital * Patients with 68Ga-PSMA and 18FDG PET scans as part of the initial workup and treatment follow-up Exclusion Criteria: * Patients who did not give their consent to use their data retrospectively
References
Publications (0)
Data not yet available
No reference posted for this study.